Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) will begin offering in Japan in January 31 a new laboratory service (for research) related to the risk of recurrence of early-stage breast cancer.
In recent years, changing eating habits and other lifestyle changes in Japan have led to ongoing increases in the number of breast cancer patients. Determining the post-operative risk of recurrence is considered to be an important indicator in the treatment of breast cancer. The selection of treatment methods involves an overall judgment based on a variety of test results. Anti-cancer drugs and other treatments are employed after determining the post-operative risk of recurrence.
Sysmex’s new laboratory service for research (C2P Breast) will involve a new technology (C2P: Cell Cycle Profiling) developed through joint research and performance evaluation tests conducted with university hospitals and other institutions. Measurement will involve studying the expression amounts of two types of proteins included in tumor tissue removed from the patient as well as their enzyme activity. In principle, these results will then be categorized into three stages (H: High; I: Intermediate; and L: Low).
Our procedure for undertaking this service will be to have customers (hospitals) send us frozen samples of patients’ tumor tissue in special test transport kits. Sysmex will measure the samples and report the results to customers (hospitals). We expect to report these results within two to three weeks of receiving the samples.
Sysmex’s Group Mid-Term Management Plan includes three core strategies*. Based on one of these core strategies, “Innovating Life Science,” we aim to create proprietary testing technologies in the life sciences field, expanding our operations in cancer and other areas of molecular diagnostics.
To date, Sysmex has developed a highly precise technology (the OSNA method, for One-step Nucleic Acid Amplification) for determining the existence of breast cancer lymph node metastasis in only around 30 minutes. We have introduced products employing this technology at numerous healthcare facilities.
Going forward, Sysmex will continue working to develop and promote high-value testing that will contribute to improvements in quality of life (QOL) for patients, the standardization of medical services and the development of personalized medicine.
[Overview of Laboratory Testing Service]
(1) Name: C2P Breast
(2) Target market: Japan
(3) Price: ¥200,000/test
(4) Flow of contracted testing:
*：Three core strategies